NCT03907475 2026-03-18
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Sumitomo Pharma America, Inc.
M.D. Anderson Cancer Center
Tesaro, Inc.
Sanofi
University of Southern California